MARATTO

article · Journal of the Egyptian National Cancer Institute

Co-adjuvant nano particles for hepatocellular carcinoma radiotherapy treatment

Abstract

HCC is one of the most life-threatening human cancers in the world. It is considered the major malignant tumor of the liver in adults and is the most common cause of death in people with cirrhosis. Chemotherapy is widely used for HCC treatment, but it has many side effects. Therefore, an alternative, safe method with low side effects, low toxicity, and a higher anti-cancer effect is in demand. In our study, we used Se-NPS alone and combined it with Gamma and UV radiation at different doses. We also used the chemotherapeutic drug sorafenib on Hep G2 cell lines to compare the effect of Se-NPS (with and without radiation) with the sorafenib group. Our results showed that Selenium alone without radiation had a lesser effect on eliminating cancer cells, with high cell viability and fewer apoptotic effects. On the other hand, Selenium combined with radiation, especially at high doses of UV (180 s) and gamma (0.2 Gy), had the highest effect on killing cancer cells. This combination resulted in significantly lower cell viability, high DNA fragmentation, and a high apoptotic effect due to a significant elevation of P53 and cytosolic cytochrome C, which was better than the Radiation-only groups.

Research topics

  • Nanoplatforms for cancer theranostics
  • Radiation Therapy and Dosimetry
  • Nanoparticle-Based Drug Delivery

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1186/s43046-025-00300-3

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.